Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Rybelsus’s appetite suppression and shifts in insulin and other hormones often lead to about 20–30% of weight loss coming from muscle unless you boost protein intake, resistance training and optimize dosing. Implementing targeted nutrition, exercise, body-composition monitoring and, if needed, alternative or adjunctive therapies can help preserve lean mass.
There are several factors to consider before switching medications; see complete details below.
Rybelsus (oral semaglutide) is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved to improve blood sugar control in type 2 diabetes. Like many weight-loss therapies, Rybelsus can lead to reductions in both fat and lean mass (including muscle). If you're asking "why does Rybelsus cause muscle loss?" you're not alone. Understanding the science behind this effect can help you decide whether to adjust your treatment, optimize your nutrition and exercise, or consider alternative therapies.
Calorie Deficit and Reduced Appetite
• Rybelsus enhances satiety by slowing gastric emptying and acting on appetite centers in the brain.
• Lower calorie intake can lead to weight loss, but without adequate protein and resistance training, some of that weight loss comes from muscle rather than fat.
Changes in Insulin Dynamics
• Improved blood sugar control means fewer insulin spikes. Insulin is an anabolic hormone that helps build and maintain muscle.
• Lower insulin levels may slightly reduce muscle-building signals, especially if protein intake isn't sufficient.
Hormonal Shifts
• GLP-1 RAs may influence other hormones (e.g., glucagon, growth hormone) that play roles in protein turnover.
• While results vary by individual, some experience more pronounced lean-mass loss than others.
Catabolic State in Weight Loss
• Any significant weight loss—whether from diet, exercise, surgery, or medication—can trigger a mild catabolic state, where the body breaks down protein to meet energy needs.
• Without targeted interventions, up to 25% of weight loss can be from lean tissue.
Baseline Muscle Mass and Activity Level
• Those with lower starting muscle mass or who are less active may see proportionally greater muscle loss.
• Sedentary lifestyle compounds lean-mass loss when appetite and calorie intake drop.
Clinical trials of GLP-1 RAs have measured body-composition changes using DEXA scans. On average:
• Total weight loss: 5–10% of baseline body weight
• Lean-mass loss: 20–30% of total weight loss
• Fat-mass loss: 70–80% of total weight loss
For example, if you lose 10 kg on Rybelsus, about 2–3 kg could be from muscle. Individual results vary based on diet, exercise, genetics and medication dose.
Maintaining muscle mass is crucial for:
• Metabolic health (higher resting metabolic rate)
• Functional strength (mobility, balance, daily activities)
• Long-term weight management (muscle burns more calories)
• Bone health (muscle contractions stimulate bone density)
Excessive muscle loss can lead to fatigue, increased injury risk and slower metabolism, making weight-regain more likely once medication stops.
Before switching, consider these steps:
Optimize Nutrition and Exercise
Assess Dose and Timing
Monitor Body Composition
Evaluate Treatment Goals
Consider Alternative or Adjunctive Therapies
• Other GLP-1 RAs (e.g., injections like liraglutide) may have slightly different weight-loss and satiety profiles, though muscle-loss risk remains.
• SGLT2 inhibitors help lower blood sugar and modestly affect weight but don't strongly alter appetite—muscle preservation may be better, but weight loss is usually less dramatic.
• DPP-4 inhibitors preserve endogenous GLP-1, generally weight-neutral but less effective for weight loss and blood sugar control.
• Combination therapy (e.g., GLP-1 RA plus SGLT2 inhibitor) may allow lower doses of each, potentially reducing muscle loss while maintaining glycemic control.
Switching medications isn't a simple decision. Weigh the benefits (A1C reduction, cardiovascular protection, weight management) against potential downsides (muscle loss, cost, side effects). Always make changes under medical guidance.
Nutrition
Exercise
Lifestyle
Discuss switching therapies with your healthcare provider if you experience:
Your doctor may recommend:
If you're experiencing unusual fatigue, muscle weakness, or other concerning symptoms while on Rybelsus, you can get instant, personalized insights through a Medically approved LLM Symptom Checker Chat Bot. This free AI-powered tool helps you understand your symptoms and determine whether you need to contact your doctor right away.
Muscle loss on Rybelsus is a known phenomenon driven by appetite suppression, hormonal shifts and the natural effects of weight loss. In many cases, targeted nutrition, exercise and dose adjustments can preserve lean tissue without abandoning a therapy that offers significant metabolic benefits.
Always discuss any serious or life-threatening concerns with your healthcare provider. They can help you balance blood sugar control, weight management and muscle health—and determine whether switching medications is the right move for you.
(References)
* Huang, J., Zhu, K., Cai, X., Yang, Y., & Wei, L. (2023). Effects of Semaglutide on Body Composition in Patients with Type 2 Diabetes Mellitus or Obesity: A Systematic Review and Meta-Analysis. *The Journal of clinical endocrinology and metabolism*, *108*(8), 1957–1969.
* Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., McGowan, B. M., Rosenstock, J., ... & Lingvay, I. (2022). Changes in body composition and fat distribution with once-weekly semaglutide 2.4 mg in adults with overweight or obesity: a post hoc analysis of the STEP 1 and STEP 3 trials. *Diabetes, obesity & metabolism*, *24*(3), 503–514.
* Li, H. X., Zheng, Y. F., Liang, S. Q., Cai, X., & Zou, S. P. (2023). GLP-1 Receptor Agonists and Sarcopenia in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Journal of clinical medicine*, *12*(13), 4504.
* Koot, J. H., van der Velde, P. K., Boons, C. C. A., Smits, M. M., Eerens, S. C. M., van den Berg, R., ... & Fliers, E. (2024). Effect of semaglutide on body composition, inflammatory markers, and metabolism in patients with type 2 diabetes and obesity: A randomized, placebo-controlled trial. *Obesity (Silver Spring, Md.)*, *32*(3), 570–579.
* Saffi, G. G., Arreche, M., Korytkowski, M., & Gondy, A. (2024). Strategies to Preserve Lean Body Mass During Weight Loss in Patients with Obesity Treated with Glucagon-Like Peptide-1 Receptor Agonists. *Current obesity reports*, *13*(2), 246–259.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.